Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,042.00 61.00 1.02% -21.80%
AbbVie 132.49 -0.54 -0.41% 19.51%
Aerie Pharmaceuticals 6.73 -0.38 -5.34% -59.96%
Alimera Sciences 4.29 -0.26 -5.71% -46.38%
Arena Pharmaceuticals 90.48 -0.53 -0.58% 16.48%
Bristol-Myers Squibb 63.57 -1.02 -1.57% -1.54%
Cardinal Health 50.70 -0.91 -1.76% -8.47%
GlaxoSmithKline 1,644.80 8.20 0.50% 19.17%
J&J 164.98 -0.27 -0.16% 0.87%
Eli Lilly 243.46 0.33 0.14% 18.10%
Merck & Co 79.98 -0.77 -0.95% -1.23%
Omeros 5.30 -0.05 -0.93% -73.06%
Pfizer 52.88 -1.17 -2.16% 44.68%
Roche Holding 361.35 -3.75 -1.03% 13.47%
Sanofi 51.24 -0.85 -1.63% 3.12%
TherapeuticsMD 0.31 -0.03 -7.79% -79.03%
Vivus 0.12 0 0% -95.70%

Indexes Price Day Year
NASDAQ 13769 -385.10 -2.72% 1.67%
US2000 1988 -36.12 -1.78% -8.34%

Vivus
Vivus, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Companys drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil, is an oral PDE5 inhibitor, which the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).